Standout Papers

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL ... 2014 2026 2018 2022 409
  1. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study (2014)
    Ian W. Flinn, Richard van der Jagt et al. Blood

Immediate Impact

1 from Science/Nature 54 standout
Sub-graph 1 of 24

Citing Papers

Chimeric antigen receptor T cell therapy for autoimmune disease
2024 Standout
CAR-T cell manufacturing: Major process parameters and next-generation strategies
2024 Standout
5 intermediate papers

Works of Peter Wood being referenced

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
2019
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
2014 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Peter Wood 700 380 556 36 1.1k
Elena Oldani 327 226 432 40 1.2k
C. Tom Kouroukis 406 337 442 48 1.1k
James Essell 264 275 475 60 1.4k
Delvyn C. Case 511 400 535 42 1.4k
Torben Mourits‐Andersen 517 425 363 32 993
Francis S. Morrison 270 327 342 54 1.3k
Cédric Garcia 207 295 143 39 960
Styliani Kokoris 269 203 210 54 855
J. A. McBride 236 172 166 33 872
Steven Andrèsen 201 135 339 48 896

All Works

Loading papers...

Rankless by CCL
2026